망막분지정맥폐쇄의 황반부종에 대한 유리체강내 베바시주맙 주입술의 효과

• 영문명: Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion
• 발행기관: 대한안과학회
• 저자명: 이한기 김현웅 윤일한,Han Kee Lee, MD, Hyun Woong Kim, MD, PhD, Il Han Yun, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume50,number12, 1800~1808쪽, 전체 9쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2009.12.15

영문 초록

Purpose: To examine the clinical effects of intravitreal bevacizumab injections for patients with macular edema secondary to branched retinal vein occlusion (BRVO). Methods: Nineteen patients (19 eyes) diagnosed with BRVO within the three month study window, having visual acuities under 0.5 and significant macular edema within two-disc diameters of the fovea were included in the present study. The author evaluated the patients’ responses to bevacizumab (1.25 mg/0.05 mL) treatment using visual acuity and central macular edema measurements. Results: The mean visual acuity improved from 1.06 (±0.10 logMAR unit) at baseline to 0.68 (±0.09 logMAR unit), 0.279 (±0.049) at one month, 0.67 (±0.9 logMAR unit) at two months, 0.61 (±0.09 logMAR unit) at three months and 0.54 (±0.10 logMAR unit) at six months. The mean central macular thickness decreased from 552.9 μm (±41.0) at baseline to 290.0 μm (±36.7) at one month, 290.0 μm (±36.7) at three months and 281.3 μm (±30.1) at six months. No adverse side effects were observed following injections. Conclusions: The observed macular edema and visual acuity improvements, as well as lack of serious adverse side effects after intravitreal bevacizumab injection, demonstrated that intravitreal bevacizumab injection may be useful for treating patients with macular edema secondary to BRVO. J Korean Ophthalmol Soc 2009;50(12):1800-1808

키워드

Bevacizumab, Branch retinal vein obstruction, Macular edema